Stocks | |||||
The table gives an overview of all stocks, alphabetically sorted. | |||||
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z |
Name | Symbol | Analysis date | Close | +/- % |
Accenture A | ACN | Oct 30, 2024 | 346.57 | -4.54 |
Acco Brands | ACCO | Oct 30, 2024 | 4.97 | +2.05 |
Accolade | ACCD | Oct 30, 2024 | 3.36 | +1.82 |
Accuray | ARAY | Oct 30, 2024 | 1.88 | +1.08 |
Acelyrin | SLRN | Oct 30, 2024 | 5.90 | -7.81 |
Achieve Life Sciences | ACHV | Oct 30, 2024 | 4.73 | +0.21 |
Achilles Therapeutics ADR | ACHL | Oct 30, 2024 | 1.02 | +2.50 |
ACI Worldwide | ACIW | Oct 30, 2024 | 49.90 | +0.02 |
Aclarion | ACON | Oct 30, 2024 | 0.20 | -0.55 |
Aclaris Therapeutics | ACRS | Oct 30, 2024 | 1.80 | +5.26 |
ACM Research A | ACMR | Oct 30, 2024 | 20.03 | +0.33 |
Acme United | ACU | Oct 30, 2024 | 39.94 | -0.79 |
ACNB | ACNB | Oct 30, 2024 | 41.99 | +1.13 |
ACRES Commercial Realty | ACR | Oct 30, 2024 | 15.17 | +2.02 |
ACRES Commercial Realty C Pref | ACR-C | Oct 30, 2024 | 24.86 | +0.04 |
ACRES Commercial Realty D Pref | ACR-D | Oct 30, 2024 | 23.14 | +0.17 |
Acri Capital Acquisition Unit | ACACU | Oct 30, 2024 | 12.94 | 0.00 |
Acrivon Therapeutics | ACRV | Oct 30, 2024 | 8.35 | +0.97 |
Actelis Networks | ASNS | Oct 30, 2024 | 1.29 | -2.27 |
Actinium Pharmaceuticals | ATNM | Oct 30, 2024 | 1.78 | -5.32 |
Active Bear ETF | HDGE | Oct 30, 2024 | 18.44 | +1.04 |
Active U.S. Real Estate Powershares | PSR | Oct 30, 2024 | 96.92 | +0.56 |
Actuate Therapeutics | ACTU | Oct 30, 2024 | 8.56 | 0.00 |
Acuity Brands | AYI | Oct 30, 2024 | 301.90 | -0.54 |
Acumen Pharmaceuticals | ABOS | Oct 30, 2024 | 3.03 | +4.30 |
Acurx Pharmaceuticals | ACXP | Oct 30, 2024 | 1.90 | -2.05 |
Acushnet | GOLF | Oct 30, 2024 | 61.65 | +0.80 |
ACV Auctions A | ACVA | Oct 30, 2024 | 17.71 | -0.62 |
ACWI Ex-US Index MSCI Ishares | ACWX | Oct 30, 2024 | 54.97 | -0.69 |
ACWI Index MSCI Ishares | ACWI | Oct 30, 2024 | 118.84 | -0.44 |
Investtech guarantees neither the entirety nor accuracy of the analyses. Any consequent exposure related to the advice / signals which emerge in the analyses is completely and entirely at the investors own expense and risk. Investtech is not responsible for any loss, either directly or indirectly, which arises as a result of the use of Investtechs analyses. Details of any arising conflicts of interest will always appear in the investment recommendations. Further information about Investtechs analyses can be found here disclaimer.
The content provided by Investtech.com is NOT SEC or FSA regulated and is therefore not intended for US or UK consumers.
Investtech guarantees neither the entirety nor accuracy of the analyses. Any consequent exposure related to the advice / signals which emerge in the analyses is completely and entirely at the investors own expense and risk. Investtech is not responsible for any loss, either directly or indirectly, which arises as a result of the use of Investtechs analyses. Details of any arising conflicts of interest will always appear in the investment recommendations. Further information about Investtechs analyses can be found here disclaimer.
The content provided by Investtech.com is NOT SEC or FSA regulated and is therefore not intended for US or UK consumers.